A group of scientists has demonstrated the ability of an innovative CRISPR gene-editing enzyme known as “Thermocas9” to distinguish with extreme precision between cancer cell DNA and healthy cell DNA. The enzyme selectively cuts cancer DNA by exploiting fundamental differences in DNA methylation, which consists of subtle chemical tags that regulate gene activity and often undergo radical changes within cancer cells. Published in the prestigious scientific journal Nature, this pioneering study marks the first time a CRISPR-based method has been used to harness methylation to directly target human cancer cells.
How methylation becomes a precise address for targeting cancer
Led by researcher Hong Li from the Van Andel Institute and researcher John van der Oost from Wageningen University & Research, this promising research builds on a unique structural feature of the Thermocas9 enzyme. Before any CRISPR system can cut DNA, it must first bind to a short recognition sequence scientifically known as a PAM (protospacer adjacent motif). Thermocas9 recognizes a specific PAM sequence that overlaps with a common human methylation site.
In healthy cells, where a genetic component in this sequence carries a methyl group, this chemical tag acts as a physical shield preventing the Thermocas9 enzyme from binding to the DNA. In cancer cells, where methylation is frequently lost at these sensitive sites, the enzyme finds a clear path to bind to the DNA and cut it freely.
In this context, researcher Hong Li stated: “Thermocas9 uses methylation as a precise address to direct strikes toward cancer cells and destroy them, while leaving healthy cells untouched.”
To understand this mechanism more deeply, DNA can be compared to a complex instruction manual. Methyl groups act as reference tags telling the cell which pages to read and which to ignore. When cells become cancerous, chaos occurs in the distribution of these tags, leading to the activation of harmful genes. The brilliance of this discovery lies in exploiting this chemical chaos as a clear signal pointing the CRISPR system to the site of the defect to correct it.
Proof of concept via breast cancer cells
To verify the effectiveness of this innovative approach, the research team transferred a modified ribonucleoprotein of the Thermocas9 enzyme into MCF-7 laboratory breast cancer cells and MCF-10A non-tumorigenic healthy breast epithelial cells. The researchers targeted specific hypomethylated regions in genes associated with breast cancer development, including genes known as ESR1 and GATA3.
The optimized Thermocas9 enzyme achieved impressive editing rates of up to 25 percent in the ESR1 gene and 78 percent in the GATA3 gene inside cancer cells. In contrast, healthy cells remained completely resistant to any gene editing, reinforcing the high selectivity of the enzyme, which depends primarily on the methylation state.
Researcher John van der Oost explained the significance of these results, saying: “Thermocas9 is the first CRISPR-associated enzyme that responds to differences in the most abundant type of DNA methylation in human cells and other eukaryotes. This means we now have a system that we can specifically direct toward cancer cells.”
Targeting these specific genes is of major importance; genes like ESR1 play a vital role in how breast cells respond to hormones, and any mutations in them are linked to aggressive types of breast cancer. By possessing the ability to exclusively target malfunctioning genes, scientists are opening a new door toward personalized therapies that minimize the harsh side effects of traditional treatments that destroy healthy and diseased cells alike.
From laboratories to future clinical therapies
Although this work is still in its early stages, with experiments conducted entirely on cell cultures and not yet tested on living organisms, researchers emphasize that these remarkable results pave the way for developing future therapies capable of destroying cancer cells with an accuracy far exceeding currently available medical approaches. In a step reflecting the importance of this discovery, Wageningen University & Research received a major EU research grant earlier this year to further develop the use of this enzyme in tumor treatment.
What makes Thermocas9 an ideal candidate for clinical applications is its compact size and exceptional thermal stability. The enzyme inherited these unique characteristics from its origins, having been extracted from a thermophilic bacterium called Geobacillus thermodenitrificans. These traits grant the enzyme significant practical advantages that make the process of delivering it into a patient’s body during clinical trials much easier and more stable compared to other enzymes.
With advanced research funded by prominent international bodies ongoing, scientists hope that within the next few years this unique enzyme will transition from preliminary laboratory experiments to human clinical trials. If its efficacy and safety are proven in living bodies with the same efficiency demonstrated in isolated cells, modern medicine will witness a true revolution in molecular oncology.
Frequently Asked Questions
What is the Thermocas9 enzyme?
It is an advanced gene-editing enzyme associated with the CRISPR system, distinguished by its unique ability to differentiate between cancer cell DNA and healthy cell DNA to cut only the diseased DNA with extreme precision.
How does methylation technology work to protect healthy cells?
In healthy cells, chemical methyl groups act as a physical shield preventing the CRISPR enzyme from binding to and cutting healthy DNA. In cancer cells, these tags are lost, allowing the enzyme to target and destroy them.
Has this gene therapy been tested on humans yet?
No, this research is still in its early laboratory stages, having been proven effective on isolated breast cancer cell cultures in the lab, with ongoing efforts to develop it in preparation for future clinical trials.
